Posts
Seasonal influenza is caused by viruses known as influenza A, B,
C, and D. These names refer to the four types of viruses, and each has a
different way of entering the human body. For example, an A virus can be
transmitted through the air, while B is most often transmitted through
secretions from the nose or mouth. C is the most commonly caught form of the
disease but does not usually spread from person to person. Influenza A viruses
are the only influenza viruses known to cause flu pandemics, i.e., global epidemics
of flu disease.
Market Dynamics
High prevalence of acute respiratory infections is expected to
propel growth of the seasonal influenza vaccines market. For instance, the
study, ‘Viral and Bacterial Etiologies of Acute Respiratory Infections among
Children under 5 Years in Senegal’, published in the journal Microbiology
Insights, in February 2018, found that adenovirus was the most prevalent (50%)
among selected virus species, followed by influenza virus, rhinovirus,
enterovirus, and respiratory syncytial virus.
Emergence of Covid-19 is expected to offer lucrative growth
opportunities for players in the seasonal influenza vaccines
market. For instance, globally, as of 4:25pm CET, 2 December 2020, there
have been 63,360,234 confirmed cases of COVID-19, including 1,475,825 deaths,
reported to the World Health Organization. Moreover, many people are getting
flu shots along with COVID testing, which is also expected to aid in growth of
the market. For instance, in December 2020, Tarrant County, TX, U.S., partnered
with pharmacies at Kroger and Tom Thumb to help provide free flu vaccines for
uninsured residents.
Moreover, increasing awareness about flu is also expected to aid
in growth of the seasonal influenza vaccines market. For instance, in September
2019, the Wisconsin Department of Health Services (DHS) announced a new
community outreach and education funding opportunity for community organizations
in order to increase awareness about the flu and the number of Wisconsinites
getting flu vaccines.
Competitive Analysis
Major players operating in
the seasonal influenza vaccines market include, Sanofi S.A., CSL Limited,
GlaxoSmithKline Plc., 7 Hills Pharma, and Medimmune, LLC.
September 2020: 7 Hills Pharma, a clinical stage immunotherapy
company focused on the development of drugs for treatment and prevention of
cancer and infectious diseases, was awarded a two-year, $2 million Small
Business Innovation Research (SBIR) grant from the National Cancer Institute
(NCI) of the U.S. National Institutes of Health to launch phase 1 trials of
lead immunostimulant to augment immuno-oncology drugs, COVID-19 and flu
vaccines.
No comments:
Post a Comment